WallStSmart

Johnson & Johnson (JNJ)vsQuantum BioPharma Ltd. (QNTM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

JNJ leads profitability with a 21.8% profit margin vs 0.0%. JNJ earns a higher WallStSmart Score of 59/100 (C).

JNJ

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 9.0Value: 3.3Quality: 6.0
Piotroski: 4/9Altman Z: 2.64

QNTM

Avoid

16

out of 100

Grade: F

Growth: 4.3Profit: 3.0Value: 5.0Quality: 2.5
Piotroski: 1/9Altman Z: -32.12
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

JNJSignificantly Overvalued (-71.4%)

Margin of Safety

-71.4%

Fair Value

$135.80

Current Price

$232.77

$96.97 premium

UndervaluedFair: $135.80Overvalued

Intrinsic value data unavailable for QNTM.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

JNJ5 strengths · Avg: 8.8/10
Market CapQuality
$536.54B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
25.9%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
21.8%9/10

Keeps 22 of every $100 in revenue as profit

Operating MarginProfitability
27.4%8/10

Strong operational efficiency at 27.4%

Free Cash FlowQuality
$1.47B8/10

Generating 1.5B in free cash flow

QNTM0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

JNJ3 concerns · Avg: 2.7/10
P/E RatioValuation
25.8x4/10

Moderate valuation

PEG RatioValuation
2.912/10

Expensive relative to growth rate

EPS GrowthGrowth
-52.9%2/10

Earnings declined 52.9%

QNTM4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$25.15M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

Comparative Analysis Report

WallStSmart Research

Bull Case : JNJ

The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.

Bull Case : QNTM

QNTM has a balanced fundamental profile.

Bear Case : JNJ

The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.

Bear Case : QNTM

The primary concerns for QNTM are Revenue Growth, EPS Growth, Market Cap.

Key Dynamics to Monitor

JNJ profiles as a mature stock while QNTM is a value play — different risk/reward profiles.

QNTM carries more volatility with a beta of 0.40 — expect wider price swings.

JNJ is growing revenue faster at 9.9% — sustainability is the question.

JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.

Bottom Line

JNJ scores higher overall (59/100 vs 16/100), backed by strong 21.8% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Johnson & Johnson

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.

Visit Website →

Quantum BioPharma Ltd.

HEALTHCARE · BIOTECHNOLOGY · USA

Quantum BioPharma Ltd. (QNTM) is an innovative biotechnology company focused on developing transformative therapies targeting oncology and autoimmune diseases. With a robust pipeline of biopharmaceutical products and a strong emphasis on research and development, Quantum leverages advanced technologies to address unmet medical needs. The company’s strategic collaborations and experienced leadership contribute to its competitive edge, positioning it well for growth in the dynamic biopharmaceutical landscape. As the market for novel therapeutics expands, QNTM presents an appealing investment opportunity for institutional investors seeking exposure in this high-potential sector.

Visit Website →

Want to dig deeper into these stocks?